GMEDGLOBUS MEDICAL INC
- Analyst Upgrades
Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $99
Wells Fargo analyst Larry Biegelsen maintains Globus Medical with a Overweight and lowers the price target from $103 to $99. ...
- GlobeNewswire
Globus Medical Reports Second Quarter 2026 Results
AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026. Second ...
- PR Newswire
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED)... ...
- GlobeNewswire
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE:GMED) breached their fiduciary ...
- GlobeNewswire
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the ...
- Analyst Upgrades
Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $100
Truist Securities analyst Richard Newitter maintains Globus Medical with a Buy and lowers the price target from $115 to $100. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Globus Medical, Lowers Price Target to $115
RBC Capital analyst Shagun Singh maintains Globus Medical with a Outperform and lowers the price target from $120 to $115. ...
- Analyst Upgrades
BMO Capital Initiates Coverage On Globus Medical with Outperform Rating, Announces Price Target of $94
BMO Capital initiates coverage on Globus Medical with a Outperform rating and announces Price Target of $94. ...
- Analyst Upgrades
Stifel Maintains Hold on Globus Medical, Lowers Price Target to $80
Stifel analyst Tom Stephan maintains Globus Medical with a Hold and lowers the price target from $95 to $80. ...
- Analyst Upgrades
Piper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $100
Piper Sandler analyst Matt O'Brien maintains Globus Medical with a Overweight and lowers the price target from $115 to $100. ...
- PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Globus Medical, Inc. (NYSE: GMED)
Purcell & Lefkowitz LLP announces that it is investigating Globus Medical, Inc. (NYSE: GMED) on behalf of the company's shareholders. The... ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $120
RBC Capital analyst Shagun Singh maintains Globus Medical with a Outperform and raises the price target from $115 to $120. ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $103
Wells Fargo analyst Larry Biegelsen maintains Globus Medical with a Overweight and lowers the price target from $104 to $103. ...
- Analyst Upgrades
Needham Maintains Buy on Globus Medical, Raises Price Target to $117
Needham analyst David Saxon maintains Globus Medical with a Buy and raises the price target from $114 to $117. ...
- GlobeNewswire
Globus Medical Reports First Quarter 2026 Results
AUDUBON, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First ...
- SEC
DEFA14A Form - Additional definitive proxy soliciting materials and Rule 14(a)(12) material - GLOBUS MEDICAL INC (0001237831) (Filer)
Additional definitive proxy soliciting materials and Rule 14(a)(12) material ...
- SEC
DEF 14A Form - Other definitive proxy statements - GLOBUS MEDICAL INC (0001237831) (Filer)
Other definitive proxy statements ...
- GlobeNewswire
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the ...
- GlobeNewswire
Globus Medical Announces Board Departure
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the ...
- Analyst Upgrades
Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $104
Wells Fargo analyst Vik Chopra maintains Globus Medical with a Overweight and raises the price target from $98 to $104. ...
- Analyst Upgrades
Barclays Maintains Overweight on Globus Medical, Raises Price Target to $123
Barclays analyst Matt Miksic maintains Globus Medical with a Overweight and raises the price target from $118 to $123. ...
- Analyst Upgrades
Needham Maintains Buy on Globus Medical, Raises Price Target to $114
Needham analyst David Saxon maintains Globus Medical with a Buy and raises the price target from $112 to $114. ...
- GlobeNewswire
Globus Medical Reports Fourth Quarter and Full Year 2025 Results
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended ...
- GlobeNewswire
Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, ...
- Analyst Upgrades
Needham Upgrades Globus Medical to Buy, Announces $112 Price Target
Needham analyst David Saxon upgrades Globus Medical from Hold to Buy and announces $112 price target. ...